azd2423
Small moleculeexperimental
Clinical trial activity
8 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2009 (NCT00940212)
Timeline
Indications
Mechanism of action
- C-C chemokine receptor type 2ANTAGONIST
CCR2 antagonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545221 ↗
Also known as
- azd2423
- azd2423
- azd2423
- azd-2423
- azd-2423
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01233830 | Phase 1 | Nov 1, 2010 | AstraZeneca, Kyushu Clinical Pharmacolgy Reasearch Clinic |
| NCT01200524 | Phase 2 | Oct 1, 2010 | AstraZeneca |
| NCT01153321 | Phase 2 | Oct 1, 2010 | AstraZeneca |
| NCT01215279 | Phase 2 | Oct 1, 2010 | AstraZeneca |
| NCT01201317 | Phase 2 | Sep 1, 2010 | AstraZeneca |
| NCT00977626 | Phase 1 | Oct 1, 2009 | AstraZeneca, Parexel |
| NCT00970775 | Phase 1 | Aug 1, 2009 | AstraZeneca, Richmond Pharmacology |
| NCT00940212 | Phase 1 | Jul 1, 2009 | AstraZeneca, Parexel |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 8 | 8 | 2 | 2009 |
| Parexel | For profit | 2 | 0 | 1 | 2009 |
| Kyushu Clinical Pharmacolgy Reasearch Clinic | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Richmond Pharmacology | For profit | 1 | 0 | 1 | 2009 |
4 organizations
Page 1 / 1